Currently, the first-line treatment of advanced HER2-positive breast cancer includes dual blockade of HER2 with the tyrosine kinase inhibitors trastuzumab and pertuzumab in combination with systemic chemotherapy with a taxane or vinorelbine [31,32,33,34,35,36]. Here, ERBB2 is linked to breast carcinoma.